PTU - Polskie Towarzystwo Urologiczne
list of articles:

Evaluation of paliative treatment of kidney cancer
Article published in Urologia Polska 1994/47/1-2.

authors

Anna Brandys, Marek Pawlicki
Z Kliniki Chemioterapii Instytutu Onkologii w Krakowie
Kierownik Kliniki: Prof. dr hab, med. M. Pawlicki
Z Przychodni Chemioterapii Instytutu Onkologii w Krakowie
Kierownik Przychodni: Lek. med. A. Brandys
Dyrektor Instytutu Onkologii w Krakowie: Prof. dr hab. med. Jan Skołyszewski

summary

Group of 139 patients with kidney cancer have been paliatively treated with systemic
chemotherapy — 53 patients, with hormonotherapy — 64 patients, and Immunotherapy — 24
patients.
The aim of the investigation was evaluation of cffectiveness of paliative treatment and
emerging the group of patients in whom this kind of treatment may be effective. Criteria of
effectiveness are: remision time and survival time.
Remarkable remision time has been achieved only in patients with lung metastasis after
nephrectomy. Immunotherapy has been proved to be the most successful method of treatment.
Treatment of primary rion-operatiw kidney cancer seeMs tO be useless.

references

  1. 1. Bergerat J.P., Herbiecht R., Durfour P. el al: \\\"Combination of recombinat interferon alpha-2a and vinblastine in advanced renal cell cancer\\\". — Cancer 1988, 62: 2330-4, —
  2. 2 Decernino JB. et al: \\\"Treatment of advanced renal cell carcinoma\\\", in: Kuss R. et al: \\\"Renal tumors. A.R. Liss, New York, 1982, 641-59. —
  3. 3. Fossa SD. et al: \\\"Recombinat interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma\\\". Cancer 57: 1700-704, 196.
  4. 4. Frank I.N., Graham S.D., Nabors /_.: \\\"Urological and male grnital cancer\\\", Clinical Oncology ACST ed.: Holled A.J., Fink D. J., Murphy G.P., 1991. —
  5. 5 Neidhart J.A.: \\\"interferon therapy for the treatment of renal Cancer Cancer 57: 1969 - 699, 1986. —
  6. 6. Miller szp. 19 MA A.B., Hoogstraten B , Sta±uet Al., Winkler A.: \\\"Raporting results of cancer treatment\\\".Cancer 47: 207, 1981. —
  7. 7. Rosenberg S.A., Lot ze L.M., et al: \\\"A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone\\\". N Engl. J. Med. 1987: 316, 889- 97. —
  8. 8. Steineck G., Strander H., Carbin B.Ii. et al: Recombinat leucocyte interferon alpha-2a ang medroxyprogesterone in advanced renal cell carcinoma, a randomized trial\\\". Acta Oncologica 1990: 155-62.

correspondence

Anna Brandys
30-058 Kraków, ul. Lea 93/99 m. 58